

## RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER

**Status:** Recruiting

### Eligibility Criteria

### Conditions & Interventions

**Conditions:**

Anatomic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8

### More Information

**Contact(s):** [sfinder@umn.edu](mailto:sfinder@umn.edu)

**Principal Investigator:** Nicole Hartung

**IRB Number:** 0123456789

**System ID:** 0123456789

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.